Funding of the programme
Global Health EDCTP3 is a ten-year programme running from 2021 to 2031.
The partnership aims for a €2 billion budget, having already secured €1.86 billion in pledges.
Strategy and scope
Global Health EDCTP3 focuses on the major infectious disease threats facing sub-Saharan Africa.
The programme focuses on all stages of clinical evaluation to deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa and strengthening research capacities to prepare and respond to re-emerging infectious diseases in the region and across the world.
What we fund
Global Health EDCTP3 grants are awarded through competitive calls for proposals. The call topics are guided by the Global Health EDCTP3 Strategic Research and Innovation Agenda, based on research priorities identified in the Annual Research and Innovation Agenda, and included in the annual work programmes.
Each work programme is developed following a comprehensive consultation process involving multiple stakeholders, including the Global Health EDCTP3 Scientific Committee and Stakeholders Group and the African and European EDCTP Association members.
The annual work programmes are approved by the Governing Board, comprising representatives from the European Commission and the EDCTP Association.
All calls for proposals are published on the European Commission’s Funding and Tender opportunities portal . They are open to the participation of researchers globally provided they team up with European and sub-Saharan African partners. Only legal entities established in any EU Member States, countries associated to Horizon Europe, or any sub-Saharan African country which is a member of the EDCTP Association are eligible to receive funding.
Target diseases
HIV
Tuberculosis (TB)
Malaria
Neglected infectious diseases
Diarrhoeal diseases
Lower respiratory tract infections
Emerging and re-emerging infectious diseases
Co-infections, co-morbidities and non-communicable diseases
Neglected infectious diseases in the scope of Global Health EDCTP3*
Buruli ulcer, Ddengue and chikungunya, Dracunculiasis (guinea-worm disease), Echinococcosis, Foodborne trematodiases, Human African trypanosomiasis (sleeping sickness), Leishmaniases, Leprosy (Hansen disease), Lymphatic filariasis, Mycetoma, onchocerciasis (river blindness), Rabies, schistosomiasis, Soil-transmitted helminthiases , Taeniasis/cysticercosis, Trachoma, Yaws.
* Based on the WHO list of neglected tropical diseases 2024, chagas disease, chromoblastomycosis and other deep mycoses, noma, scabies and other ectoparasites, and snakebite envenoming are currently not in the scope of Global Health EDCTP3.
Our scope also includes overarching areas such as antimicrobial resistance (AMR), climate-crisis-provoked changes in infectious disease incidence and digital health solutions.
Medical interventions
We support clinical studies on medicinal products designed to detect, prevent or treat target diseases. These include novel drug treatments and formulations, new therapeutic regimens, microbicides, vaccines and diagnostics.
Types of research
We support all phases of clinical evaluation (phases I-IV), with a particular emphasis on late-stage product development, including phase III and IV clinical trials, pharmacovigilance and post-licensing effectiveness studies, product-focused implementation research and field trials.
These are funded through 'Research and innovation actions' (RIA) that establish new knowledge and/or explore a new or improved technology, product, process, service or solution.
Research capacity
Global Health EDCTP3 makes an important contribution to the development of clinical research capacity in sub-Saharan Africa and strengthens the enabling environment for conducting clinical trials and other research activities. We support researchers at various career stages, from master’s and PhD training through to fellowships. We also support activities strengthening the ethical, regulatory and legal framework for conducting trials.
These are funded through 'Coordination and support actions' (CSA) that improve cooperation between partners, for example when it comes to standardisation, dissemination, awareness-raising, communication and networking activities, policy dialogues, mutual learning or studies.
Monitoring and evaluation
The Monitoring & Evaluation (M&E) system of Global Health EDCTP3 is designed to track and assess progress toward achieving the programme objectives. It ensures accountability, informs decision-making and optimises resource use.
Grounded in a results-based management approach, the M&E system focuses on key indicators at various levels - activities, outputs, outcomes and impact - providing a comprehensive view of our performance and impact, relying on robust data collection and technically sound methodologies.
Monitoring
The monitoring component of the M&E system includes several key elements aimed at systematically tracking progress:
‣ Programme logic: a visual framework that outlines how our activities are expected to lead to outcomes and impact, while identifying external factors (assumptions) that influence success. The Programme logic is grounded in the Strategic Research and Innovation Agenda (SRIA), and aligned with the mission and goals of Global Health EDCTP3 as set out in Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe.
‣ Indicator list: a structured set of metrics to measure progress at multiple levels, incorporating Horizon Europe-mandated indicators as well as those specific to Global Health EDCTP3’s objectives.
‣ M&E plan: detailed guidelines on data collection methods, roles and responsibilities, reporting, and timelines for each indicator.
‣ Interactive dashboard: a tool that enables stakeholders to dynamically explore M&E data, allowing them to filter and combine information by various subgroups.
Evaluation
Evaluation complements monitoring by providing deeper insights into the effectiveness and impact of our activities. In addition to continuous monitoring, Global Health EDCTP3 will undergo external evaluations commissioned by the Horizon Europe programme at midterm and upon completion of the initiative. These evaluations will assess the overall impact and effectiveness of our work.
The first interim external evaluation report of Global Health EDCTP3 was published in June 2024 and is accessible here.
Beyond external evaluations, Global Health EDCTP3 may also commission internal evaluations as needed, focusing on specific themes or areas of interest. These internal evaluations will be conducted if information gaps or areas requiring in-depth analysis emerge during the program's implementation.